PF-3845

Research use only, not for human use.

PF-3845 is a potent, selective and irreversible FAAH inhibitor with Ki of 230 nM, showing negligible activity against FAAH2.

PF-3845 is a potent, selective and irreversible FAAH inhibitor with Ki of 230 nM, showing negligible activity against FAAH2.

PF-3845 (0.5 nM-10 μM; 40 min) inhibits human FAAH-1 (IC50=18 nM) in a concentration-dependent manner, and shows negligible activity against FAAH-2 (IC50>10 μM) in COS-7 cells.PF-3845 (0.1-1000 μM; 48 h) significantly decreases the Colo-205 cell viability.

PF-3845 (1-30 mg/kg; p.o.) produces cannabinoid receptor-dependent reductions in inflammatory pain in rat.PF-3845 (10 mg/kg; a single i.p.) selectively inhibits FAAH in mice for up to 24 hours.PF-3845 (10 mg/kg; a single i.p.) causes a dramatic and sustained elevation in Anandamide (AEA) in mice. Animal Model:Male Sprague-Dawley rats (200g- 250g) are injected CFADosage:1, 3, 10, 30 mg/kg Administration:Oral administration Result:Caused a dose-dependent inhibition of mechanical allodynia with a minimum effective dose (MED) of 3 mg/kg.

PF3845 | PF-3845 | PF 3845

Metabolic Enzyme/Protease

FAAH

FAAH

Inflammation/Immunology

——

1196109-52-0

456.46

C??H??F?N?O?

>98% (HPLC)

DMSO:45.7 mg/mL (100 mM);Ethanol:22.8 mg/mL (50 mM)

O=C(N1CCC(CC2=CC=CC(OC3=NC=C(C(F)(F)F)C=C3)=C2)CC1)NC4=CC=CN=C4

N-3-Pyridinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methyl]-1-piperidinecarboxamide

(-20℃)

With Ice Pack

≥ 2 years